Krystal Biotech Announces RMAT Designation Granted by FDA to KB707 for the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer

Rhea-AI Summary

Krystal Biotech (NASDAQ: KRYS) announced on February 9, 2026 that the FDA granted RMAT designation to KB707 for treatment of advanced or metastatic non-small cell lung cancer (NSCLC). The designation recognizes preliminary clinical activity from the ongoing KYANITE-1 trial and offers expedited development benefits such as rolling review and intensive FDA interaction. Enrollment in KYANITE-1 continues; additional data will be presented at upcoming scientific conferences and the trial is listed as NCT06228326.

Positive

• FDA granted RMAT designation to KB707 on February 9, 2026
• RMAT provides Fast Track and Breakthrough-like benefits for development
• KYANITE-1 showed durable responses and meaningful tumor reductions
• This is Krystal's second RMAT designation, signaling regulatory progress

Negative

• KYANITE-1 enrollment is ongoing, so evidence remains preliminary
• No regulatory approval or pivotal readout announced yet

News Market Reaction

-0.05%

1 alert

-0.05% News Effect

-$4M Valuation Impact

$7.91B Market Cap

1.1x Rel. Volume

On the day this news was published, KRYS declined 0.05%, reflecting a mild negative market reaction. This price movement removed approximately $4M from the company's valuation, bringing the market cap to $7.91B at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

ClinicalTrials.gov ID: NCT06228326

1 metrics

ClinicalTrials.gov ID NCT06228326 KYANITE-1 study identifier for inhaled KB707 in NSCLC

Market Reality Check

Price: $272.65 Vol: Volume 313,208 is near th...

normal vol

$272.65 Last Close

Volume Volume 313,208 is near the 20-day average of 304,792 (~1.03x average). normal

Technical Shares at $272.74 are trading above the $182.21 200-day moving average, reflecting a strong pre-news uptrend.

Peers on Argus

KRYS was up 1.91% while close peers showed mixed moves (e.g., ARWR -1.5%, ACAD -...

KRYS was up 1.91% while close peers showed mixed moves (e.g., ARWR -1.5%, ACAD -2%, MIRM +0.45%). This pattern points to stock-specific dynamics rather than a sector-wide move.

Historical Context

5 past events · Latest: Jan 08 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 08	Clinical update	Positive	+1.0%	Positive interim KB407 Phase 1 CORAL-1 cystic fibrosis data with CFTR delivery.
Jan 07	Clinical call setup	Neutral	-1.2%	Announcement of investor call to discuss highest dose CORAL-1 KB407 data.
Jan 05	Conference appearance	Neutral	-0.9%	Planned presentation at 44th J.P. Morgan Healthcare Conference with investor meetings.
Nov 26	Conference appearance	Neutral	+0.8%	Participation in 8th Evercore Healthcare Conference with fireside chat and meetings.
Nov 03	Earnings report	Positive	+0.2%	Strong Q3 2025 results with high VYJUVEK revenue, margins and cash balance.

Pattern Detected

Recent news, including clinical and earnings updates, has produced relatively modest single-day price reactions, with mostly aligned sentiment and market response.

Recent Company History

Over the past several months, KRYS has reported multiple clinical and financial milestones. A positive KB407 interim update on Jan 8, 2026 led to a +1.03% move, while the preceding update call announcement on Jan 7, 2026 saw a -1.21% reaction. Conference participation news on Jan 5, 2026 and Nov 26, 2025 drove small moves within 1%. Third-quarter 2025 earnings on Nov 3, 2025 with strong revenue and cash figures corresponded to a modest +0.17% move. Overall, KRYS has historically shown contained single-day reactions to both clinical and financial disclosures.

Market Pulse Summary

This announcement highlights that KB707 for advanced NSCLC received RMAT designation, giving KRYS en...

Analysis

This announcement highlights that KB707 for advanced NSCLC received RMAT designation, giving KRYS enhanced interaction with the FDA and potential expedited pathways. In recent history, clinical updates and earnings reports have produced relatively modest single-day moves, such as +1.03% on a KB407 interim readout and +0.17% on Q3 2025 results. Investors may watch upcoming KYANITE-1 data disclosures, regulatory interactions, and broader pipeline progress as key markers of how this designation translates into future milestones.

Key Terms

regenerative medicine advanced therapy (rmat) designation, non-small cell lung cancer, tumor microenvironment, interleukin-2, +4 more

8 terms

regenerative medicine advanced therapy (rmat) designation regulatory

"FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to KB707..."

A Regenerative Medicine Advanced Therapy (RMAT) designation is a U.S. regulatory status given to certain cell, gene, or tissue-based treatments that show promise for serious conditions and early clinical evidence of benefit. It signals that regulators will provide extra guidance and expedited review steps—like giving a promising project a “fast pass” through some development checkpoints—which can shorten time to market and reduce regulatory risk, making the program more valuable and noteworthy to investors.

non-small cell lung cancer medical

"...for the treatment of advanced or metastatic non-small cell lung cancer (NSCLC)."

A broad category of lung tumors that grow from the cells lining the airways and make up the majority of lung cancer cases; it includes several subtypes that behave and respond to treatment differently, like different models of the same car family. It matters to investors because its large patient population and variety of treatment options — surgery, traditional chemo, targeted drugs and immunotherapies — create major markets where clinical trial results, drug approvals or changing treatment guidelines can quickly affect a company’s revenue and stock value.

tumor microenvironment medical

"...expression of interleukin-2 and interleukin-12 in the tumor microenvironment..."

The tumor microenvironment is the immediate area surrounding a cancer cell, made up of nearby cells, blood vessels, and support structures that influence how the cancer grows and spreads. It functions like a bustling neighborhood that can either help or hinder the tumor’s development. For investors, understanding changes in this environment can signal the effectiveness of treatments and potential shifts in a cancer-related market.

interleukin-2 medical

"...designed to drive sustained, localized expression of interleukin-2 and interleukin-12..."

A small protein that acts as a signal in the immune system, interleukin-2 tells white blood cells to grow and become more active—think of it as a coach rallying immune players. Investors watch it because drugs that mimic or modify this signal can boost anti‑cancer immunity or treat immune disorders, but they also carry safety risks and regulatory hurdles that affect clinical trial success and commercial value.

interleukin-12 medical

"...expression of interleukin-2 and interleukin-12 in the tumor microenvironment..."

Interleukin-12 is a naturally occurring protein that acts as a messenger to activate and direct immune cells, helping the body fight infections and cancer. Investors pay attention because drugs that boost, mimic or block this messenger can become important therapies or cause safety and regulatory setbacks; positive or negative clinical trial and approval news about IL-12 pathways can materially affect a biotech company's value, like a signal that changes traffic flow in a busy market.

fast track regulatory

"The designation provides all the benefits of the FDA's Fast Track and Breakthrough Therapy..."

A fast track designation is a regulatory label that speeds up the review and communication between a drug developer and regulators for treatments addressing serious illnesses or unmet medical needs. For investors, it matters because it can shorten development time and reduce regulatory delays—like getting a VIP lane at the airport—raising the chance of earlier market access and potential revenue, though it does not guarantee approval.

breakthrough therapy regulatory

"The designation provides all the benefits of the FDA's Fast Track and Breakthrough Therapy..."

A breakthrough therapy is a regulatory designation granted to an experimental drug or treatment when early clinical evidence indicates it could offer a substantial improvement over existing options for a serious or life‑threatening condition. For investors it matters because the label brings faster, more intensive interaction with regulators and can shorten development and review time—like a VIP fast‑track toward potential approval, reducing time and risk before a product can reach the market.

accelerated approval regulatory

"...endpoints to support potential accelerated approval, and novel approaches to satisfy..."

Accelerated approval is a process that allows new medical treatments to be approved more quickly than usual if they address serious or life-threatening conditions and show promising early results. For investors, it signals that a treatment may reach the market sooner, potentially boosting a company's prospects, but it also involves some uncertainty since full evidence of effectiveness is still being gathered.

AI-generated analysis. Not financial advice.

PITTSBURGH, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that the United States Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to KB707, the Company’s redosable immunotherapy designed to drive sustained, localized expression of interleukin-2 and interleukin-12 in the tumor microenvironment, for the treatment of advanced or metastatic non-small cell lung cancer (NSCLC).

“The FDA’s decision to grant RMAT designation to KB707 reflects both the urgent unmet need for new NSCLC therapies as well as the promising early clinical evidence of efficacy we have observed with inhaled KB707 in patients with advanced NSCLC,” said Suma Krishnan, President of Research and Development at Krystal Biotech. “This is the second RMAT designation granted to a Krystal program and, as such, we know first-hand the benefits that this designation can provide to accelerate development and shorten the path to a potential approval. We are excited to work closely with the FDA to maximize the potential impact of our KB707 program for patients with NSCLC.”

The FDA’s RMAT designation is intended to support and expedite the development of regenerative medicine therapies, including gene therapies. An investigational regenerative medicine therapy is eligible for the RMAT designation if it is intended to treat, modify, reverse or cure a serious or life-threatening disease or condition and preliminary clinical evidence indicates potential to address unmet medical needs for that disease or condition. The designation provides all the benefits of the FDA's Fast Track and Breakthrough Therapy designations, including potential for rolling review, intensive FDA guidance and interaction, and organizational commitment from senior managers at the FDA, as well as the ability to work more closely and frequently with the FDA to discuss innovative trial designs, surrogate or intermediate endpoints to support potential accelerated approval, and novel approaches to satisfy post-approval requirements.

Data to support the FDA’s RMAT designation included early clinical evidence from the Company’s ongoing KYANITE-1 study that demonstrated consistent and meaningful antitumor activity, including durable responses and clinically significant tumor reductions, in patients with heavily pre-treated advanced NSCLC receiving inhaled KB707. Enrollment in KYANITE-1 is ongoing, and further details will be presented at upcoming scientific conferences. Additional details about the study can be found at www.clinicaltrials.gov under NCT identifier NCT06228326.

About Krystal Biotech, Inc.
Krystal Biotech, Inc. (NASDAQ: KRYS) is a fully integrated, commercial-stage, global biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK^®, the Company’s first commercial product, is the first-ever redosable gene therapy and the first genetic medicine approved in the United States, Europe, and Japan for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. For more information, please visit http://www.krystalbio.com, and follow @KrystalBiotech on LinkedIn and X (formerly Twitter).

CONTACT
Investors and Media:                                                             
Stéphane Paquette, PhD
Krystal Biotech
spaquette@krystalbio.com

FAQ

What does the FDA RMAT designation for KB707 (KRYS) mean for drug development?

It means accelerated regulatory support and closer FDA interaction to speed development. According to Krystal, RMAT offers rolling review, intensive guidance, and potential for surrogate endpoints to support accelerated approval.

What clinical evidence supported the RMAT designation for KB707 (KRYS)?

Early KYANITE-1 data showed consistent antitumor activity with durable responses. According to Krystal, inhaled KB707 produced meaningful tumor reductions in heavily pre-treated advanced NSCLC patients.

Is KB707 approved for NSCLC after the February 9, 2026 RMAT designation?

No, RMAT is a development designation and is not an approval. According to Krystal, KB707 remains investigational with ongoing KYANITE-1 enrollment and further data planned for scientific conferences.

Where can investors find the KB707 trial details and identifier for KRYS?

Trial details are posted on ClinicalTrials.gov under identifier NCT06228326. According to Krystal, KYANITE-1 enrollment is ongoing and additional study details are available on the registry.

How might RMAT designation affect KRYS shareholder timelines or regulatory interactions?

RMAT may shorten development timelines through increased FDA engagement and rolling review. According to Krystal, the designation enables more frequent FDA discussions on trial design and potential accelerated approval pathways.